TPD52L3

Across TCGA pan-cancer cohorts, TPD52L3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TPD52L3 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TPD52L3 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TPD52L3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, PRAD, and LUAD are the cancer types where TPD52L3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	1.000	0.530	.018	30	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	II,III,IV	0.237	0.709	.039	3	view →
COAD	OS	Median	All	1.000	0.523	.046	2	view →
SKCM	OS	Median	All	0.150	0.328	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TPD52L3–UCEC (DFS)

Open the UCEC breakdown →